<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations><gtr:collaborator url="http://gtr.ukri.org:80/organisation/3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9"><gtr:id>3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9</gtr:id><gtr:name>University of Oxford</gtr:name><gtr:address><gtr:line1>University Chest</gtr:line1><gtr:line2>Wellington Square</gtr:line2><gtr:line4>Oxford</gtr:line4><gtr:postCode>OX1 2JD</gtr:postCode><gtr:region>South East</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/82321AD2-CD2E-456C-9395-59CF155A3EC8"><gtr:id>82321AD2-CD2E-456C-9395-59CF155A3EC8</gtr:id><gtr:name>Sanofi</gtr:name><gtr:address><gtr:line1>174 avenue de France</gtr:line1><gtr:line4>Paris cedex 13</gtr:line4><gtr:postCode>75635</gtr:postCode><gtr:region>Outside UK</gtr:region><gtr:country>France</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/2DB7ED73-8E89-457A-A395-FAC12F929C1A"><gtr:id>2DB7ED73-8E89-457A-A395-FAC12F929C1A</gtr:id><gtr:name>University of Edinburgh</gtr:name><gtr:address><gtr:line1>Old College</gtr:line1><gtr:line2>South Bridge</gtr:line2><gtr:line3>Mayfield Road</gtr:line3><gtr:line4>Edinburgh</gtr:line4><gtr:postCode>EH8 9YL</gtr:postCode><gtr:region>Scotland</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/3B1E5961-8677-4A32-B15C-12FB968FA163"><gtr:id>3B1E5961-8677-4A32-B15C-12FB968FA163</gtr:id><gtr:name>University of Pennsylvania</gtr:name><gtr:address><gtr:line1>3451 Walnut Street,</gtr:line1><gtr:line2>Suite P-221</gtr:line2><gtr:line3>Franklin Building</gtr:line3><gtr:line4>Philadelphia</gtr:line4><gtr:postCode>PA 19104</gtr:postCode><gtr:region>Outside UK</gtr:region><gtr:country>United States</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/C008EA20-84DD-4EEC-9F16-8FCA7C86311C"><gtr:id>C008EA20-84DD-4EEC-9F16-8FCA7C86311C</gtr:id><gtr:name>Imperial Innovations</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/67ABD4F2-1AB0-483C-9F74-C6E9B0460BF9"><gtr:id>67ABD4F2-1AB0-483C-9F74-C6E9B0460BF9</gtr:id><gtr:name>NHS Lothian</gtr:name><gtr:address><gtr:line1>Royal Victoria Hospital</gtr:line1><gtr:line2>13 Craigleith Road</gtr:line2><gtr:postCode>EH4 2DN</gtr:postCode><gtr:region>Scotland</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator></gtr:collaborations><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/46387D84-F71E-4B7D-8C7D-9C288F113510"><gtr:id>46387D84-F71E-4B7D-8C7D-9C288F113510</gtr:id><gtr:name>Imperial College London</gtr:name><gtr:address><gtr:line1>South Kensington Campus</gtr:line1><gtr:line2>Exhibition Road</gtr:line2><gtr:line4>London</gtr:line4><gtr:postCode>SW7 2AZ</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/46387D84-F71E-4B7D-8C7D-9C288F113510"><gtr:id>46387D84-F71E-4B7D-8C7D-9C288F113510</gtr:id><gtr:name>Imperial College London</gtr:name><gtr:address><gtr:line1>South Kensington Campus</gtr:line1><gtr:line2>Exhibition Road</gtr:line2><gtr:line4>London</gtr:line4><gtr:postCode>SW7 2AZ</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9"><gtr:id>3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9</gtr:id><gtr:name>University of Oxford</gtr:name><gtr:address><gtr:line1>University Chest</gtr:line1><gtr:line2>Wellington Square</gtr:line2><gtr:line4>Oxford</gtr:line4><gtr:postCode>OX1 2JD</gtr:postCode><gtr:region>South East</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/82321AD2-CD2E-456C-9395-59CF155A3EC8"><gtr:id>82321AD2-CD2E-456C-9395-59CF155A3EC8</gtr:id><gtr:name>Sanofi</gtr:name><gtr:address><gtr:line1>174 avenue de France</gtr:line1><gtr:line4>Paris cedex 13</gtr:line4><gtr:postCode>75635</gtr:postCode><gtr:region>Outside UK</gtr:region><gtr:country>France</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/2DB7ED73-8E89-457A-A395-FAC12F929C1A"><gtr:id>2DB7ED73-8E89-457A-A395-FAC12F929C1A</gtr:id><gtr:name>University of Edinburgh</gtr:name><gtr:address><gtr:line1>Old College</gtr:line1><gtr:line2>South Bridge</gtr:line2><gtr:line3>Mayfield Road</gtr:line3><gtr:line4>Edinburgh</gtr:line4><gtr:postCode>EH8 9YL</gtr:postCode><gtr:region>Scotland</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/3B1E5961-8677-4A32-B15C-12FB968FA163"><gtr:id>3B1E5961-8677-4A32-B15C-12FB968FA163</gtr:id><gtr:name>University of Pennsylvania</gtr:name><gtr:address><gtr:line1>3451 Walnut Street,</gtr:line1><gtr:line2>Suite P-221</gtr:line2><gtr:line3>Franklin Building</gtr:line3><gtr:line4>Philadelphia</gtr:line4><gtr:postCode>PA 19104</gtr:postCode><gtr:region>Outside UK</gtr:region><gtr:country>United States</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/C008EA20-84DD-4EEC-9F16-8FCA7C86311C"><gtr:id>C008EA20-84DD-4EEC-9F16-8FCA7C86311C</gtr:id><gtr:name>Imperial Innovations</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/67ABD4F2-1AB0-483C-9F74-C6E9B0460BF9"><gtr:id>67ABD4F2-1AB0-483C-9F74-C6E9B0460BF9</gtr:id><gtr:name>NHS Lothian</gtr:name><gtr:address><gtr:line1>Royal Victoria Hospital</gtr:line1><gtr:line2>13 Craigleith Road</gtr:line2><gtr:postCode>EH4 2DN</gtr:postCode><gtr:region>Scotland</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/34D3D542-EE34-47C2-B114-637F9B78F83C"><gtr:id>34D3D542-EE34-47C2-B114-637F9B78F83C</gtr:id><gtr:firstName>Eric</gtr:firstName><gtr:surname>Alton</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=MC_PC_12033"><gtr:id>05469409-5174-4A95-90AB-E271AE9A2AAE</gtr:id><gtr:title>A randomised double-blind placebo controlled Phase 2B clinical trial of repeated application of gene therapy in patients with Cystic Fibrosis</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Intramural</gtr:grantCategory><gtr:grantReference>MC_PC_12033</gtr:grantReference><gtr:abstractText>In the UK, a child is born with cystic fibrosis (CF) every day of the year. This inherited disease used to be fatal in infancy, but conventional treatments in specialist clinics mean that most now survive to young adulthood. However, for the 9,000 patients in the UK, the long-term prospects are for a progressive loss of lung function from repeated and ultimately fatal lung infections. This results in significant NHS costs for both hospital-based and outpatient care. As CF always arises from a defect in a single gene, called CFTR, the simplest theoretical cure is to deliver a working copy of the CFTR gene to the cells lining the lung. The UK CF Gene Therapy Consortium, comprising world-leading teams at Oxford, Edinburgh and Imperial College London, set out 10 years ago to solve this problem. The proposed trial is the next critical test of this potentially life-changing therapy. Specifically, the study will test whether monthly delivery of a working copy of the CFTR gene to the lungs for 1 year can improve the lung function of CF patients. This novel and exciting study builds on preliminary studies by the Consortium which have: a) Identified the best way of transferring the CFTR gene into the lungs, b) Established the optimal safe dose following single administration in CF patients, c) Shown that it can work as predicted for over a month following a single dose, d) Followed ~200 CF patients for 2 years (Run-in study) to identify the best ways of measuring the effects of the gene and e) Undertaken safety studies in animals species that allow regulatory approval of the trial. 120 CF patients will be treated at the Brompton Hospital, London and Western General Hospital, Edinburgh. The great majority of patients have already participated in the Run-in study and are ready and willing to participate. We are therefore well placed to measure the impact of the gene therapy on patient well-being; the most important measurement being an improvement in how the lungs move air in and out (lung function). We will also look for evidence of reduced lung mucus, inflammation and infection. Funding is requested to cover the direct cost of the trial, comprising salaries for the clinical and scientific support team, patient and NHS costs, and the analysis of samples. Importantly, the ethical issues have been extensively discussed with the UK Gene Therapy Advisory Committee: the age limit for inclusion in the trial at 12 years balances the increased likelihood of benefit for those with milder disease, against any possible toxic effects on the growing lung.</gtr:abstractText><gtr:technicalSummary>RESEARCH DESIGN: Double-blind, placebo controlled parallel group study of monthly aerosol of gene therapy formulation over 12 months. POPULATION: Inclusion: a) Confirmed diagnosis of Cystic Fibrosis; b) 12 years or older; c) Mild to moderate lung disease based on FEV1 of 50-90% predicted; d) Any CFTR mutation; e) Clinical stability for 4 weeks prior to first dose; f) Written informed consent from patient (16 years or older) or parent if younger child; assent from a child; g) Willing to adhere to contraceptive requirements. Exclusion: a) Current participation in another interventional trial; b) Infection with Burkholderia cepacia complex organisms, Mycobacterium abscessus or MRSA; c) Previous spontaneous pneumothorax unless pleurodesed (bronchoscopic group only); d) Recurrent severe haemoptysis; e) Current smoker; f) Significant comorbidity; g) Using second line immunosuppressants; h) Pregnant or breast-feeding. INTERVENTIONS: Twelve 5 ml doses of pGM169/GL67A or placebo (0.9% saline) delivered via an AeroEclipse nebuliser at four weekly intervals; subgroup (n=24) to be dosed nasally. OUTCOME MEASURES: a) Primary: Percent change in percent predicted FEV1 from baseline to after the 12th dose. b) Secondary: Lung clearance index, chest CT scan, Quality of Life measures (using CFQ-UK validated questionnaire), other spirometric markers, exercise capacity, activity monitoring, serum calprotectin, sputum microbiology, cell counts and soluble inflammatory markers. Gene expression: Transgene mRNA and potential difference in nose and lung (subgroup only). ASSESSMENT AND FOLLOW UP: Subjects will undergo: screening, 12 x dosing, and 2 x follow up at 14 and 28 days after the 12th dose. The first 20 patients will undergo visits on Day 2 post-dosing for the first three doses. SAMPLE SIZE: Based on our extensive data from the Run-in Study, we estimate the standard deviation (SD) of the percent change in percent predicted FEV1 over 12 months to be 10.0%. 120 evaluable patients (60 active, 60 placebo) will give us 90% power at the 5% significance level (2-sided) to detect a difference of 6% between the randomised groups in the mean change from baseline. This is widely considered clinically relevant. STATISTICAL ANALYSIS: Comparison of the two randomised groups in terms of mean percent change in percent predicted FEV1 from baseline to end of treatment. An analysis of covariance (ANCOVA) model will include baseline percent predicted FEV1 together with the other variables used in the randomisation algorithm as covariates. The treatment effect will be presented as an adjusted difference in mean percent change along with its corresponding 95% confidence interval. TIMETABLE: Start March 2012 with first dosing May 2012; the majority of the patients are already recruited. Completion of: three doses in first 20 subjects (Aug 2012); all patients receiving one dose (Dec 2012); final dosing in all patients (Dec 2013); data analysis (Mar 2014).</gtr:technicalSummary><gtr:fund><gtr:end>2014-06-30</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2012-03-01</gtr:start><gtr:type>EXPENDITURE_ACTUAL</gtr:type><gtr:valuePounds>3663639</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Edinburgh</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Institute of Genetics &amp; Molecular Medicine</gtr:department><gtr:description>University of Pennsylvania and The UK Cystic Fibrosis Gene Therapy Consortium</gtr:description><gtr:id>6292231A-002A-4C27-B772-B973E8121186</gtr:id><gtr:impact>Publication: Hum Gene Ther Clin Dev. 2013 Sep;24(3):108-15. doi: 10.1089/humc.2012.249. Epub 2013 Jul 19.</gtr:impact><gtr:outcomeId>FRGSbshUf4P-1</gtr:outcomeId><gtr:partnerContribution>University of Edinburgh:
* Collecting and shipping of samples
The Trustees of the University of Pennsylvania:
* To perform the immunological assays element comprised in the study.</gtr:partnerContribution><gtr:piContribution>Collecting, and shipping of samples</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2013-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>NHS Lothian</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>Secondment of Research Nurse Manager</gtr:description><gtr:id>C2254CD8-1FD0-43FE-BEFC-8291A91B761B</gtr:id><gtr:impact>EME report
Lancet Resp Med paper</gtr:impact><gtr:outcomeId>56b879a4cfdf91.11066283-1</gtr:outcomeId><gtr:partnerContribution>The research nurse manager oversaw the clinical governance aspects of the multidose trial in the NHS Lothian hospitals: liaised directly with consultants and clinical fellows involved in assessment and processing of patients enrolled into the trial; supervised recruitment; contacted trial participants when necessary; liaised with WT-CRF staff to facilitate the input and upkeep of clinical records pertaining to the trial; prepared sites for MHRA inspections; ensured trial documentation was up-to-date, accurate, and adhered to GMP standards.</gtr:partnerContribution><gtr:piContribution>With major input from Ann Doherty, clinical trials co-ordinator (science-side), managed and co-ordinated the CF gene therapy studies at the two sites in NHS Lothian (WGH and RHSC), maintaining communication and continuity of the research programme with the staff at the Medical Genetics Section, University of Edinburgh and staff in other sites in the UK Gene Therapy Consortium. Liaised with CF Physicians in Scotland to enable patient recruitment into the study and inform them of their patients' progress in the studies.</gtr:piContribution><gtr:sector>Public</gtr:sector><gtr:start>2008-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Oxford</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Gene Medicine Research Group</gtr:department><gtr:description>Sanofi Genzyme and The UK Cystic Fibrosis Gene Therapy Consortium</gtr:description><gtr:id>0B414916-64D4-4B91-A4F8-CC4FDFDC0EA5</gtr:id><gtr:impact>Publication: Biomaterials. 2013 Dec;34(38):10267-77. doi: 10.1016/j.biomaterials.2013.09.023. Epub 2013 Oct 3.</gtr:impact><gtr:outcomeId>BpvkupGsxe7-1</gtr:outcomeId><gtr:partnerContribution>University of Oxford, University of Edinburgh: 
* Research from lab to running the clinical trial.
Genzyme Corporation:
* Supply GL67
Imperial Innovations Limited
* IP Management</gtr:partnerContribution><gtr:piContribution>Research from lab to running the clinical trial.</gtr:piContribution><gtr:sector>Public</gtr:sector><gtr:start>2007-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Pennsylvania</gtr:collaboratingOrganisation><gtr:country>United States of America</gtr:country><gtr:description>University of Pennsylvania and The UK Cystic Fibrosis Gene Therapy Consortium</gtr:description><gtr:id>79E2C2F1-B237-4741-AA8D-833B4B5A652C</gtr:id><gtr:impact>Publication: Hum Gene Ther Clin Dev. 2013 Sep;24(3):108-15. doi: 10.1089/humc.2012.249. Epub 2013 Jul 19.</gtr:impact><gtr:outcomeId>FRGSbshUf4P-2</gtr:outcomeId><gtr:partnerContribution>University of Edinburgh:
* Collecting and shipping of samples
The Trustees of the University of Pennsylvania:
* To perform the immunological assays element comprised in the study.</gtr:partnerContribution><gtr:piContribution>Collecting, and shipping of samples</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2013-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Edinburgh</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Institute of Genetics &amp; Molecular Medicine</gtr:department><gtr:description>Sanofi Genzyme and The UK Cystic Fibrosis Gene Therapy Consortium</gtr:description><gtr:id>0C1049A4-5401-459E-813A-FFF27FD25FB8</gtr:id><gtr:impact>Publication: Biomaterials. 2013 Dec;34(38):10267-77. doi: 10.1016/j.biomaterials.2013.09.023. Epub 2013 Oct 3.</gtr:impact><gtr:outcomeId>BpvkupGsxe7-3</gtr:outcomeId><gtr:partnerContribution>University of Oxford, University of Edinburgh: 
* Research from lab to running the clinical trial.
Genzyme Corporation:
* Supply GL67
Imperial Innovations Limited
* IP Management</gtr:partnerContribution><gtr:piContribution>Research from lab to running the clinical trial.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2007-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Sanofi</gtr:collaboratingOrganisation><gtr:country>United States of America</gtr:country><gtr:department>Genzyme Corporation</gtr:department><gtr:description>Sanofi Genzyme and The UK Cystic Fibrosis Gene Therapy Consortium</gtr:description><gtr:id>9F3716BE-D9FB-493E-8D2A-4C3675B35C56</gtr:id><gtr:impact>Publication: Biomaterials. 2013 Dec;34(38):10267-77. doi: 10.1016/j.biomaterials.2013.09.023. Epub 2013 Oct 3.</gtr:impact><gtr:outcomeId>BpvkupGsxe7-2</gtr:outcomeId><gtr:partnerContribution>University of Oxford, University of Edinburgh: 
* Research from lab to running the clinical trial.
Genzyme Corporation:
* Supply GL67
Imperial Innovations Limited
* IP Management</gtr:partnerContribution><gtr:piContribution>Research from lab to running the clinical trial.</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2007-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Imperial Innovations</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>Sanofi Genzyme and The UK Cystic Fibrosis Gene Therapy Consortium</gtr:description><gtr:id>BAC2B3BE-9846-40BE-86FF-155BFB1E14D0</gtr:id><gtr:impact>Publication: Biomaterials. 2013 Dec;34(38):10267-77. doi: 10.1016/j.biomaterials.2013.09.023. Epub 2013 Oct 3.</gtr:impact><gtr:outcomeId>BpvkupGsxe7-4</gtr:outcomeId><gtr:partnerContribution>University of Oxford, University of Edinburgh: 
* Research from lab to running the clinical trial.
Genzyme Corporation:
* Supply GL67
Imperial Innovations Limited
* IP Management</gtr:partnerContribution><gtr:piContribution>Research from lab to running the clinical trial.</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2007-01-01</gtr:start></gtr:collaborationOutput></gtr:collaborationOutputs><gtr:disseminationOutputs><gtr:disseminationOutput><gtr:description>Laboratory tour by members of the public who are supporters of the charity The Flutterby FUNdraisers</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:geographicReach>Regional</gtr:geographicReach><gtr:id>B69F7D2D-2F24-4E23-AD46-C3E38D4A7758</gtr:id><gtr:impact>Presentations about the gene therapy work carried out by the UKCFGTC, hands on practicals, lab demos, lunch and photo opportunity of cheque presentation.</gtr:impact><gtr:outcomeId>56b9f9c9488510.88738565</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Supporters</gtr:primaryAudience><gtr:year>2015</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Annual North American CF Conference - British Society for Gene Therapy</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>91AE48DF-B663-49EA-B21D-FFD3D751757D</gtr:id><gtr:impact>Highlight awareness of GT and CF to the wider public</gtr:impact><gtr:outcomeId>56cef006f41ce2.37500639</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2013</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Presentation to Parents of Children with CF (RHSC Edinburgh)</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>Regional</gtr:geographicReach><gtr:id>DCC60F0A-FFB9-4A25-BA7E-AEF2F54918C7</gtr:id><gtr:impact>Chris Boyd and a member of his lab team gave presentations on the clinical trial work and ongoing research being undertaken by the UKCFGT Consortium. Approx 15 parents and carers of children with cystic fibrosis attended the talks and were able to informally ask questions regarding present and future studies that their children may be eligible to take part in.</gtr:impact><gtr:outcomeId>56cc6e92952f06.97779720</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Patients, carers and/or patient groups</gtr:primaryAudience><gtr:year>2015</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>German Society for Gene Therapy (Vienna)</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>174A9E86-A592-45C5-A014-DD3483354BCA</gtr:id><gtr:impact>Extensive interest in world 1st non-viral trial of Gene Therapy aimed at Clinical improvement. Discussions underway with Pharma for follow on study.</gtr:impact><gtr:outcomeId>56ced00f720bc3.63695133</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2015</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>3rd Annual CF Science Appreciation Dinner (2015)</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>C6398B00-A7AB-405A-BD51-D0C77909A0A1</gtr:id><gtr:impact>3rd Annual CF Science Appreciation Dinner. 25 fund raisers, care givers and scientists involved with cystic fibrosis research. Networking and speaking event which sparked questions and discussions.</gtr:impact><gtr:outcomeId>56c348a8a3a780.54309789</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Patients, carers and/or patient groups</gtr:primaryAudience><gtr:year>2015</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Gene Therapy Consortium Meeting- Public Announcement streamed to Edinburgh site</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>Regional</gtr:geographicReach><gtr:id>D78FD4AD-0C8F-4E50-8F14-AB0E514C8F22</gtr:id><gtr:impact>On 30th May 2015 Eric Alton presented the clinical trial results of the UK Cystic Fibrosis Gene Therapy Multidose study before it was published in the Lancet. His presentation was attended in London by parents/carers/interested parties of CF patients and streamed online to patients. A link was set up at the University of Edinburgh (IGMM) where approx 20 parents/carers/interested parties of patients came together to watch and participate in the live link. After the presentation both scientific and clinical members of the UKCFGTC were on hand to chat and answer questions over light refreshments.</gtr:impact><gtr:outcomeId>56cc72e361ccd8.41538703</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Study participants or study members</gtr:primaryAudience><gtr:year>2015</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Science in Health</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>0A2F86FB-F38D-484F-9A21-5B193F416798</gtr:id><gtr:impact>Highlighting the awareness of CF and GT to the wider public


Stimulated enthusiasm around the Gene Therapy trial.</gtr:impact><gtr:outcomeId>5460af1ce19948.42557724</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2014</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>BBC Radio London (2015)</gtr:description><gtr:form>A broadcast e.g. TV/radio/film/podcast (other than news/press)</gtr:form><gtr:geographicReach>Regional</gtr:geographicReach><gtr:id>3E3124D2-882A-4739-AFB3-FF260E929E90</gtr:id><gtr:impact>BBC Radio London Breakfast Show. Broadcast interview to discuss clinical trial results.</gtr:impact><gtr:outcomeId>56c346b482b113.89043085</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2015</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>US CF Research Scientist Appreciation Dinner 2015</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>Local</gtr:geographicReach><gtr:id>B1342E3E-9E64-4DAB-8562-64B7F7159127</gtr:id><gtr:impact>Dinner attended by scientists with history of research in Cystic Fibrosis to talk to supporters and patients' families</gtr:impact><gtr:outcomeId>56cf3ee0202c58.18440227</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Patients, carers and/or patient groups</gtr:primaryAudience><gtr:year>2015</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Presentation to Newcastle Adult PIC Site</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>Regional</gtr:geographicReach><gtr:id>C93FA271-53EC-4E62-808D-CEAAC3457222</gtr:id><gtr:impact>Presentation by Dr Alastair Innes to medical staff at Institute of Cellular Medicine, University of Newcastle, to inform them of our clinical trial progress to help with recruitment of adult patients.</gtr:impact><gtr:outcomeId>56b9f3ffd3ad60.95611793</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2013</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Presentation to Newcastle Pediatric PIC Site</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>Regional</gtr:geographicReach><gtr:id>307829F8-FC08-40F0-B16B-FC0E11AB899C</gtr:id><gtr:impact>Presentation by Dr David Armstrong to medical staff at Royal Victoria Infirmary, Newcastle, to inform them of our clinical trial progress to help with recruitment of pediatric patients.</gtr:impact><gtr:outcomeId>56b9f2591aa554.25665740</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2013</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Cystic Fibrosis Trust: Lungs for the Life Conference (Manchester)</gtr:description><gtr:form>A formal working group, expert panel or dialogue</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>DA5FE6FD-4152-4F3B-A928-909BF27B35E0</gtr:id><gtr:impact>Extensive interest in world 1st non-viral trial of Gene Therapy aimed at Clinical improvement. Discussions underway with Pharma for follow on study.</gtr:impact><gtr:outcomeId>56ceee387d0ec8.20304552</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2015</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Rotary Club of Durham Presentation</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>Regional</gtr:geographicReach><gtr:id>A50BA8DA-CCCE-45EE-8006-88F9A48BA54A</gtr:id><gtr:impact>Lunch for 40 Rotarians with talk by Alastair Innes. Two group members have CF grandchildren and there are other interested members including several doctors and pharmacists, a writer and other retired professionals. A member specifically asked Alastair to talk about the trial and how it effected his grandchild who is part of the Edinburgh Trial. The talk included the daily procedures during a Dosing visit and what was expected over the year of the trial.</gtr:impact><gtr:outcomeId>56b9f6f40db534.67659650</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2013</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Cafe Scientific Talk Bradfield College 2015</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>Regional</gtr:geographicReach><gtr:id>61E7693D-82EF-4976-80D6-C3331CE567E3</gtr:id><gtr:impact>Science discussion evening event
Extensive Q &amp;amp; A session</gtr:impact><gtr:outcomeId>56cf3b81bed0f8.75196215</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2015</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Imperial College Fringe Event</gtr:description><gtr:form>Participation in an open day or visit at my research institution</gtr:form><gtr:geographicReach>Local</gtr:geographicReach><gtr:id>D081EDBB-A827-4306-AE54-8A7311AECDEB</gtr:id><gtr:impact>Communication of science to the public


Wide spread enthusiasm amongst participates.</gtr:impact><gtr:outcomeId>YqqvwCKKZG5</gtr:outcomeId><gtr:partOfOfficialScheme>true</gtr:partOfOfficialScheme><gtr:presentationType>Workshop Facilitator</gtr:presentationType><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2013</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>BBC Radio2 Jeremy Vine Show (2015)</gtr:description><gtr:form>A broadcast e.g. TV/radio/film/podcast (other than news/press)</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>6D0CA73A-C734-413C-8AC9-616E7CA7263A</gtr:id><gtr:impact>BBC Radio2 Jeremy Vine Show. Broadcast interview to discuss clinical trial results.</gtr:impact><gtr:outcomeId>56c3476ef0ef25.09935081</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2015</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>BBC2 TV Victoria Derbyshire Show (2015)</gtr:description><gtr:form>A broadcast e.g. TV/radio/film/podcast (other than news/press)</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>8EE7A15A-3606-4FF3-BDFC-08F5E3150079</gtr:id><gtr:impact>BBC2 TV Victoria Derbyshire Show. Broadcast interview to discuss clinical trial results.</gtr:impact><gtr:outcomeId>56c347e7a0cc03.32314265</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2015</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>ECFS Diagnostic Network Working Group - CFTR gene therapy: What does the future hold</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>F534B4AD-DE21-4B82-AFF1-7DECBED3A7E1</gtr:id><gtr:impact>Highlighted awareness of CF and GT to the wider public</gtr:impact><gtr:outcomeId>56cf015dc44447.60321574</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2016</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Gene Therapy Consortium meeting - public Announcement streamed to Edinburgh site</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>Regional</gtr:geographicReach><gtr:id>7CF57869-D804-4481-8BDC-B6B934368FF8</gtr:id><gtr:impact>On 30th May 2015 Professor Alton presented the Clinical trail results of the UK CF Gene Therapy Multidose study before it was published in the Lancet. His presentation was attended in London by parents/ carers / interested parties of CF patients and streamed online to patients. A link was set up at the University of Edinburgh (IGMM) where approx 20 parents / careers/ interested parties of patients came together to watch and participate in the live link. After the presentation both scientific and clinical members of the UKCFGTC were on hand to chat and answer questions over light refreshments.</gtr:impact><gtr:outcomeId>56d581c1dafe42.92735527</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Study participants or study members</gtr:primaryAudience><gtr:year>2015</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Presentation Karolinska Institute 2015</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>AA851617-ACFD-427D-9DC1-3EA2F163AEE7</gtr:id><gtr:impact>Dissemination of scientific findings in a general CF gene therapy context to range of practitioners</gtr:impact><gtr:outcomeId>56dedda5842311.82187066</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2015</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>British Society for Gene and Cell Therapy Annual meeting - A Phase IIb double-blind, placebo-controlled trial of non-viral mediated gene therapy for cystic fibrosis</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>6BB5AD72-2E1E-4940-9BD7-CF326FB78DD1</gtr:id><gtr:impact>Highlighted awareness of CF and GT to the wider public</gtr:impact><gtr:outcomeId>56cef32d2adb93.70268937</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2015</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>CF Unite, Nottingham - CF Genetics and Gene Therapy</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>37F8290B-4BBB-470D-9059-1652B79812F9</gtr:id><gtr:impact>Highlighted awareness of CF and GT to the wider public</gtr:impact><gtr:outcomeId>56cef0ce161656.80320006</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2013</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Navigating The Future Of Healthcare - Academy Of Medical Sciences - 2016/07/08</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>4AE22AB3-C1E5-489D-B70C-50B2C9BACCA5</gtr:id><gtr:impact>Science education workshop. Encouraging career participation and development especially for women scientist.</gtr:impact><gtr:outcomeId>58befcc5a4b738.60387721</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Postgraduate students</gtr:primaryAudience><gtr:url>https://acmedsci.ac.uk/more/events/navigating-the-future-of-healthcare</gtr:url><gtr:year>2016</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>The Institute of Genetic Medicine Seminar - Lung Gene Therapy</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>F4295879-99AA-4DE0-8E6E-2C8168BC5CB2</gtr:id><gtr:impact>Highlighted awareness of CF and GT to the wider public</gtr:impact><gtr:outcomeId>56ceffca553724.99782587</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2015</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>BTS Winter Meeting (London)</gtr:description><gtr:form>A formal working group, expert panel or dialogue</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>47279075-FC8B-4189-AAFE-8D210315A943</gtr:id><gtr:impact>Extensive interest in world 1st non-viral trial of Gene Therapy aimed at Clinical improvement. Discussions underway with Pharma for follow on study.</gtr:impact><gtr:outcomeId>56cef0fbab7bd8.54413117</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2015</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Rare Disease Awareness Day</gtr:description><gtr:form>Participation in an open day or visit at my research institution</gtr:form><gtr:geographicReach>Regional</gtr:geographicReach><gtr:id>383E5FB1-06A4-414B-AF2D-86A15154D061</gtr:id><gtr:impact>Highlighting the awareness of CF and GT to the wider public.

Stimulated enthusiasm for Science and Medical topics to the wider public.</gtr:impact><gtr:outcomeId>UxQUHPbd3Ck</gtr:outcomeId><gtr:partOfOfficialScheme>true</gtr:partOfOfficialScheme><gtr:presentationType>Workshop Facilitator</gtr:presentationType><gtr:primaryAudience>Schools</gtr:primaryAudience><gtr:year>2011,2012,2013</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Talk to CF Trial patients, families and the public re; GT Phase 2b Trial results launch</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>28BAAEF9-7D69-4E0A-B334-C38B33326EAA</gtr:id><gtr:impact>On 30th May 2015 Professor Alton presented the Clinical trail results of the UK CF Gene Therapy Multidose study before it was published in the Lancet. His presentation was attended in London by parents/ carers / interested parties of CF patients and streamed online to patients.</gtr:impact><gtr:outcomeId>56d5827a5823f7.55288568</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Study participants or study members</gtr:primaryAudience><gtr:year>2015</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Alport Society Annual Meeting - CF Gene Therapy</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>74C7B2BD-9277-4FE4-8B52-46793F3388B2</gtr:id><gtr:impact>Highlighted awareness of CF and GT to the wider public</gtr:impact><gtr:outcomeId>56cefeadd59ff9.06156068</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2015</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Doors Open Day (IGMM Edinburgh)</gtr:description><gtr:form>Participation in an open day or visit at my research institution</gtr:form><gtr:geographicReach>Local</gtr:geographicReach><gtr:id>ACFDF4FB-7DB2-4E26-86A4-D5BEF0872AB0</gtr:id><gtr:impact>Poster Presentation by Ann Doherty on the UKCFGTC work and chatting to members of the public about the gene therapy clinical trials and work.</gtr:impact><gtr:outcomeId>56b9f8c0ecdfc5.20369166</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2015</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Cafe Scientific Talk (Bradfield College 2015)</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>Local</gtr:geographicReach><gtr:id>4ABD9477-D253-4467-8663-7E99B60420C3</gtr:id><gtr:impact>Science discussion evenning event at Bradfield College. Wide ranging audience from school children to CF care givers and relatives. Talk stimulated extensive discussion and questions.</gtr:impact><gtr:outcomeId>56c349aebc9bb2.85585112</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Schools</gtr:primaryAudience><gtr:year>2015</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Alports Syndrome International Workshop (2015)</gtr:description><gtr:form>A formal working group, expert panel or dialogue</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>174D8BB0-E48F-4944-A333-12C6C5A7AF9C</gtr:id><gtr:impact>Presentation to ~150 people attending international workshop on Alports syndrome. Individuals included patients, carers and scientific researchers. Introduced new therapeutic concepts. Wide ranging discussions followed.</gtr:impact><gtr:outcomeId>56c34b27b3c3d8.52911491</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2015</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Controlled Release Society Annual meeting - A Phase IIb double-blind, placebo-controlled trial of non-viral mediated gene therapy for cystic fibrosis</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>31E5C787-D76F-4ABD-83CE-2B5D5458A16C</gtr:id><gtr:impact>Highlighted awareness of CF and GT to the wider public</gtr:impact><gtr:outcomeId>56cefd848e2ce9.77055559</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2015</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>BBC Radio 5Live Breakfast Show (2015)</gtr:description><gtr:form>A broadcast e.g. TV/radio/film/podcast (other than news/press)</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>FB15FEEC-1C2D-4C5E-8A38-D164309BB330</gtr:id><gtr:impact>BBC Radio 5Live Breakfast show. Broadcast interview to discuss clinical trial results</gtr:impact><gtr:outcomeId>56c34717452b24.53624775</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2015</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Interview with New Scientist journalist 2015</gtr:description><gtr:form>A magazine, newsletter or online publication</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>FDA3DE96-03E1-462B-AF4D-C49459BE8C70</gtr:id><gtr:impact>Following the interview an article was published in New Scientist which was directly shaped by quotes that I had given.</gtr:impact><gtr:outcomeId>56cf3d524662a5.36054732</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2015</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>BBC Radio Scotland Interview</gtr:description><gtr:form>A broadcast e.g. TV/radio/film/podcast (other than news/press)</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>454120FB-4FFB-44AC-96D7-FC4FC3FCD4D7</gtr:id><gtr:impact>Dr Chris Boyd was interviewed by BBC Radio Scotland to publicise the newly released clinical trial results published in the Lancet Medical Journal.</gtr:impact><gtr:outcomeId>56b9fdc88f5467.37655522</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2015</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>German Mukoviscidose Gesellschaft Annual Meeting - Moving forward with CF Gene Therapy</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>A26490A7-B816-49FC-8D6A-7A24BAF6AC48</gtr:id><gtr:impact>Highlighted awareness of CF and GT to the wider public</gtr:impact><gtr:outcomeId>56cefe36417d13.40541699</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2015</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>RSM Cystic Fibrosis Symposium</gtr:description><gtr:form>A formal working group, expert panel or dialogue</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>5515007C-088D-4326-9B22-BD867D8CD7EA</gtr:id><gtr:impact>Extensive interest in world 1st non-viral trial of Gene Therapy aimed at Clinical improvement. Discussions underway with Pharma for follow on study.</gtr:impact><gtr:outcomeId>56ceee6c792693.33095432</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2015</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>European Respiratory Society Annual Meeting - Update on CF Gene Therapy</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>A9E50A59-EB5D-43B5-9E42-D4DB0C2AE104</gtr:id><gtr:impact>Highlighted awareness of CF and GT to the wider public</gtr:impact><gtr:outcomeId>56cefeff448228.19914971</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2015</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Quintiles - Success and challenges in CF gene therapy</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>Regional</gtr:geographicReach><gtr:id>DA2044C9-86F3-44D2-8556-83CAF7560C20</gtr:id><gtr:impact>Highlighted awareness of CF and GT to the wider public</gtr:impact><gtr:outcomeId>56cefde0a64145.68108073</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Industry/Business</gtr:primaryAudience><gtr:year>2015</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Cystic Fibrosis Foundation Research Conference: Pushing the Frontiers (Chantily, VA)</gtr:description><gtr:form>A formal working group, expert panel or dialogue</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>9B88450F-9A6B-4C0A-B5EE-B8B7712A4FB6</gtr:id><gtr:impact>Planning future strategy for the CF Foundation</gtr:impact><gtr:outcomeId>56ced05012d418.11651834</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2015</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Pirbright Research Institute - Lung Gene Therapy</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>C2EFC4FB-9936-44C5-92CD-E78522C2400A</gtr:id><gtr:impact>Highlighted awareness of CF and GT to the wider public</gtr:impact><gtr:outcomeId>56cef1566c73c3.19219078</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2015</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Radio Ireland interview</gtr:description><gtr:form>A press release, press conference or response to a media enquiry/interview</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>633FB71D-9399-44C6-BA64-46A487171508</gtr:id><gtr:impact>Radio interview</gtr:impact><gtr:outcomeId>56cf3c5b0c1bc9.60020294</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2015</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Annual A-Level GCSE student Practical</gtr:description><gtr:form>Participation in an open day or visit at my research institution</gtr:form><gtr:geographicReach>Local</gtr:geographicReach><gtr:id>6785EC68-2495-442A-A7F9-4B5460160E4D</gtr:id><gtr:impact>Annually 5-6 attend the workshop, often inspired to take up careers in Science and Medicine.

Increase in applications to Science and Medical Universities.</gtr:impact><gtr:outcomeId>Rt4u2VMdiqU</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:presentationType>Workshop Facilitator</gtr:presentationType><gtr:primaryAudience>Schools</gtr:primaryAudience><gtr:year>2009,2010,2011,2012,2013</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>EME Board Evening Seminar</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>91A322B5-67B1-4FC8-BBFC-62408DCCB091</gtr:id><gtr:impact>The talk resulted in numerous questions and discussions around the Multi-Dose trial and EMEs input.

After the talk, there was positive feedback which has led to a stronger understanding of the working relationship within EME.</gtr:impact><gtr:outcomeId>5460ae44583be4.33333122</gtr:outcomeId><gtr:partOfOfficialScheme>true</gtr:partOfOfficialScheme><gtr:primaryAudience>Other academic audiences (collaborators, peers etc.)</gtr:primaryAudience><gtr:year>2014</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Television Interview (STV)</gtr:description><gtr:form>A broadcast e.g. TV/radio/film/podcast (other than news/press)</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>A7AC67F5-562D-425A-A604-EE19BDB0A731</gtr:id><gtr:impact>Dr Chris Boyd was interviewed by Scottish Television (STV) to publicise the newly released clinical trial results published in the Lancet Medical Journal.</gtr:impact><gtr:outcomeId>56b9fffbafca47.52267971</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:url>http://www.youtube.com/watch?v=6QdjkPTdTsU</gtr:url><gtr:year>2015</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Clinical advances in CF 2016 Conferences (London)</gtr:description><gtr:form>A formal working group, expert panel or dialogue</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>B7D05E30-FFA3-481B-985C-32D37354DF9E</gtr:id><gtr:impact>Extensive interest in world 1st non-viral trial of Gene Therapy aimed at Clinical improvement. Discussions underway with Pharma for follow on study.</gtr:impact><gtr:outcomeId>56cef154971ea2.16855942</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2016</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Presentation to University College (Wadham College Oxford) on Gene Therapy for Cystic Fibrosis</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>Local</gtr:geographicReach><gtr:id>C53718A9-A550-45D9-AE9B-CCA610D81D35</gtr:id><gtr:impact>Presentation to University College (Wadham College Oxford) on Gene Therapy for Cystic Fibrosis.
30 under graduate students attended a presentation on Gene Therapy for Cystic Fibrosis: Finally Turning the Hype into Clinical Progess. This sparked questions and discussion afterwards and gave students more awareness of Gene Therapy and how it can help sufferers of Cystic Fibrosis</gtr:impact><gtr:outcomeId>58b7fd430bac84.05635054</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Undergraduate students</gtr:primaryAudience><gtr:year>2016</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Presentation to Science Media Centre 2015</gtr:description><gtr:form>A press release, press conference or response to a media enquiry/interview</gtr:form><gtr:geographicReach>Regional</gtr:geographicReach><gtr:id>9D5B9F6C-9601-442F-A0A7-41E248DB0E4A</gtr:id><gtr:impact>Presentation followed by Q&amp;amp;A session with journalists from national newspapers and magazines to publicise results from recent clinical trial</gtr:impact><gtr:outcomeId>56cf3e01620612.90886389</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Media (as a channel to the public)</gtr:primaryAudience><gtr:year>2015</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Print or online media coverage of the trial results</gtr:description><gtr:form>A magazine, newsletter or online publication</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>0F5BB359-A834-47DA-8556-E425DCEA5CF0</gtr:id><gtr:impact>Additional media coverage of the trial results included articles in the following:

New Scientist - Gene therapy works in cystic fibrosis for the first time, Penny Sarchet.
The Independent - Gene therapy offers hope to cystic fibrosis patients after successful trials, Steve Connor
The Guardian - Gene therapy for cystic fibrosis may be possible by 2020, scientists say, Sarah Boseley
The Financial Times - UK gene therapy trial offers hope on cystic fibrosis, Clive Cookson
The Mirror - UK scientists developing cystic fibrosis treatment which could be available in five years, John Von Radowitz
ITV.com - Trial findings boost cystic fibrosis gene therapy hopes
The Daily Mail - Breakthrough for cystic fibrosis sufferers as scientists use gene therapy to significantly improve the function of patients' lungs, Sophie Borland
The Daily Mail - Spraying new genes into your lungs could ease misery of cystic fibrosis, Diana Pilkington
BBC - Gene therapy stabilises lungs of cystic fibrosis patients, Pallab Ghosh
Bloomberg - Cystic Fibrosis Study Points Way Forward for Gene Therapy, Makiko Kitamura
The Telegraph - Cystic fibrosis hope as new gene therapy improves condition, Sarah Knapton
Wired - Cystic Fibrosis improved with gene therapy for first time, Liat Clark
Gizmodo - Gene Therapy Finally Shown to Help Cystic Fibrosis Sufferers, Jamie Condliffe
Channel 5 News - Gene therapy could offer new hope for cystic fibrosis sufferers
RTE - Encouraging results from Cystic Fibrosis gene therapy trial
The Herald - Trial boosts CF gene therapy hopes, John von Radowitz (PA)
The Irish Times - Gene therapy shows promise in cystic fibrosis research
The Huffington Post - Cystic Fibrosis Treatment: Gene Therapy Clinical Trials Show 'Encouraging But Modest Results', Natasha Hinde</gtr:impact><gtr:outcomeId>56d85ed1d3a638.98524951</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2015</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Imperial Festival</gtr:description><gtr:form>Participation in an open day or visit at my research institution</gtr:form><gtr:geographicReach>Local</gtr:geographicReach><gtr:id>617C0A18-B6DA-4405-9CDD-7108E769568F</gtr:id><gtr:impact>Communication of Science related topics to the wider public.

Widespread enthusiasm amongst participants.</gtr:impact><gtr:outcomeId>YQmnfBwvyLN</gtr:outcomeId><gtr:partOfOfficialScheme>true</gtr:partOfOfficialScheme><gtr:presentationType>Workshop Facilitator</gtr:presentationType><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2013</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>38th European Cystic Fibrosis Conference</gtr:description><gtr:form>A formal working group, expert panel or dialogue</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>DB6E38C9-7B56-437F-BC06-AFB767200DBF</gtr:id><gtr:impact>Extensive interest in world 1st non-viral trial of Gene Therapy aimed at Clinical improvement. Discussions underway with Pharma for follow on study.</gtr:impact><gtr:outcomeId>56ced0835e68f9.60667764</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Other audiences</gtr:primaryAudience><gtr:year>2015</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>North America CF Conference (Phoenix)</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>66E8710B-9031-4120-942E-5352586FFA4F</gtr:id><gtr:impact>Extensive interest in world 1st non-viral trial of Gene Therapy aimed at Clinical improvement. Discussions underway with Pharma for follow on study.</gtr:impact><gtr:outcomeId>56cecfe54c7373.61770832</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2015</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>BBC Radio Oxford Drivetime Show (2015)</gtr:description><gtr:form>A broadcast e.g. TV/radio/film/podcast (other than news/press)</gtr:form><gtr:geographicReach>Regional</gtr:geographicReach><gtr:id>CA336F08-426A-49AC-B142-10F0E5144FF9</gtr:id><gtr:impact>BBC Radio Oxford Drivetime Show. Broadcast interview to discuss clinical trial results.</gtr:impact><gtr:outcomeId>56c347b2dc49e5.61369308</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2015</gtr:year></gtr:disseminationOutput></gtr:disseminationOutputs><gtr:exploitationOutputs/><gtr:furtherFundingOutputs><gtr:furtherFundingOutput><gtr:amountPounds>750000</gtr:amountPounds><gtr:country>Liechtenstein, Principality of</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>GT consortia Core Funding</gtr:description><gtr:end>2017-06-02</gtr:end><gtr:fundingOrg>Medicor Foundation</gtr:fundingOrg><gtr:id>841C052F-463A-495D-8A88-27560D11D482</gtr:id><gtr:outcomeId>56d8741bc0c267.44330068</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2015-04-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>142693</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>An application to fund the UK CF Gene Therapy Consortium core costs</gtr:description><gtr:end>2016-08-02</gtr:end><gtr:fundingOrg>Cystic Fibrosis Trust</gtr:fundingOrg><gtr:id>9ABEB980-4ADB-4949-90CD-F3634F834854</gtr:id><gtr:outcomeId>5457a1c3e58f83.44609070</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2014-03-01</gtr:start></gtr:furtherFundingOutput></gtr:furtherFundingOutputs><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs><gtr:intellectualPropertyOutput><gtr:description>The patent covers a gene therapy product to treating CF and claims cover a pharmaceutical composition made up of an unique DNA sequence for the expression of CFTR combined with a charged lipid carrier which allows the product to be formulated as an aerosol for more efficient delivery. Also claims dose.</gtr:description><gtr:grantRef>MC_PC_12033</gtr:grantRef><gtr:id>3F0E61ED-5C25-4319-8F12-4424BB45FB44</gtr:id><gtr:impact>Orphan Drug Designation has been granted in both US and Europe for a non-viral CF gene therapy product subject of this patent.</gtr:impact><gtr:licensed>No</gtr:licensed><gtr:outcomeId>aG37vD8uw1y</gtr:outcomeId><gtr:patentId>WO2013061091</gtr:patentId><gtr:protection>Patent granted</gtr:protection><gtr:title>A CF Gene therapy product</gtr:title><gtr:yearProtectionGranted>2012</gtr:yearProtectionGranted></gtr:intellectualPropertyOutput><gtr:intellectualPropertyOutput><gtr:description>The patent claims a DNA insert (a &amp;quot;construct&amp;quot;) which when introduced into a human system causes gene expression which can counter certain diseases or symptoms. The notable inventive and novel aspect is the inclusion of a CpG free promoter/enhancer driving CFTR gene expression as part of a gene therapy product for treatment of cystic fibrosis. This is Background IP to the project.</gtr:description><gtr:grantRef>MC_PC_12033</gtr:grantRef><gtr:id>E3E55526-ADEB-47DE-8E71-E47910A8F72D</gtr:id><gtr:impact>Orphan Drug Designation has been granted in both US and Europe for a non-viral CF gene therapy product incorporating the construct.</gtr:impact><gtr:licensed>No</gtr:licensed><gtr:outcomeId>o5eqwcaH7fD</gtr:outcomeId><gtr:patentId>EP2007895</gtr:patentId><gtr:protection>Patent granted</gtr:protection><gtr:title>DNA construct with hCEFI promoter driving gene expression</gtr:title><gtr:yearProtectionGranted>2006</gtr:yearProtectionGranted></gtr:intellectualPropertyOutput></gtr:intellectualPropertyOutputs><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Membership of strategy implementation board of the cystic fibrosis trust.</gtr:description><gtr:geographicReach>National</gtr:geographicReach><gtr:id>F675E9D7-101B-4728-A804-1237DA3AEF7E</gtr:id><gtr:outcomeId>ThqrUieiAnb</gtr:outcomeId><gtr:type>Participation in a advisory committee</gtr:type></gtr:policyInfluenceOutput></gtr:policyInfluenceOutputs><gtr:productOutputs><gtr:productOutput><gtr:clinicalTrial>true</gtr:clinicalTrial><gtr:description>A non-viral gene therapy for cystic fibrosis consisting of CFTR-encoding plasmid complexed with GL67A lipid carrier, recently completed a phase IIb double-blind, placebo controlled clinical trial. To date the principle sources of funding have been from the CF Trust and NIHR EME.</gtr:description><gtr:id>9C2CE218-F073-432C-9326-F13B6A8708EA</gtr:id><gtr:impact>In addition to the completion of the Phase IIb clinical trial in 2014, Orphan Drug Designation was granted in Europe and US in 2014 for the product. A patent claiming the CpG free promoter/enhancer driving transgene expression has also been granted in Europe and US.</gtr:impact><gtr:outcomeId>5460b725600877.40076866</gtr:outcomeId><gtr:stage>Early clinical assessment</gtr:stage><gtr:status>Actively seeking support</gtr:status><gtr:title>A non-viral gene therapy for cystic fibrosis consisting of CFTR-encoding plasmid complexed with GL67A lipid carrier</gtr:title><gtr:type>Therapeutic Intervention - Cellular and gene therapies</gtr:type><gtr:yearDevCompleted>2014</gtr:yearDevCompleted></gtr:productOutput></gtr:productOutputs><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs/><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication><gtr:id>AB2158B3-6F7A-4FC5-95AA-FC48E0DB0274</gtr:id><gtr:title>Transgene sequences free of CG dinucleotides lead to high level, long-term expression in the lung independent of plasmid backbone design.</gtr:title><gtr:parentPublicationTitle>Biomaterials</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/349abbba72aad8393d81a62ac4161966"><gtr:id>349abbba72aad8393d81a62ac4161966</gtr:id><gtr:otherNames>Bazzani RP</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0142-9612</gtr:issn><gtr:outcomeId>58a2e7d1b51dd0.09551275</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>11860F6D-4A68-47F0-9F8B-4A37DDDBFCF9</gtr:id><gtr:title>Genetic medicines for CF: Hype versus reality.</gtr:title><gtr:parentPublicationTitle>Pediatric pulmonology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/22f4b0c676241659342f5bf9f5c2ce79"><gtr:id>22f4b0c676241659342f5bf9f5c2ce79</gtr:id><gtr:otherNames>Alton EW</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1099-0496</gtr:issn><gtr:outcomeId>58a2e7281bd521.84747006</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>802EDEBD-CC6D-4526-9B08-600354C625C8</gtr:id><gtr:title>Special focus issue on the annual meeting of the British Society for Gene and Cell Therapy.</gtr:title><gtr:parentPublicationTitle>Human gene therapy</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/0a56ab8bae8e53f00ab8cbd3baf06f39"><gtr:id>0a56ab8bae8e53f00ab8cbd3baf06f39</gtr:id><gtr:otherNames>Nicklin SA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1043-0342</gtr:issn><gtr:outcomeId>56d422890c53f5.47757187</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>2AF6872E-E724-4289-B719-F6AE480C5392</gtr:id><gtr:title>A Phase I/IIa Safety and Efficacy Study of Nebulized Liposome-mediated Gene Therapy for Cystic Fibrosis Supports a Multidose Trial.</gtr:title><gtr:parentPublicationTitle>American journal of respiratory and critical care medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/22f4b0c676241659342f5bf9f5c2ce79"><gtr:id>22f4b0c676241659342f5bf9f5c2ce79</gtr:id><gtr:otherNames>Alton EW</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1073-449X</gtr:issn><gtr:outcomeId>56cde4b0442957.07462084</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>F4C8CA03-730B-4CDC-BE73-2DB600434D43</gtr:id><gtr:title>S120 Update on the UK CF Gene Therapy Consortium Multidose, Non-Viral, Gene Therapy Trial</gtr:title><gtr:parentPublicationTitle>Thorax</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a4c54c9c32ea0c00850296e893333283"><gtr:id>a4c54c9c32ea0c00850296e893333283</gtr:id><gtr:otherNames>Alton E</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:outcomeId>545758b8468542.53083256</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>8D18B51F-F380-4AD6-8323-52BB1520AB68</gtr:id><gtr:title>Repeated nebulisation of non-viral CFTR gene therapy in patients with cystic fibrosis: a randomised, double-blind, placebo-controlled, phase 2b trial.</gtr:title><gtr:parentPublicationTitle>The Lancet. Respiratory medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/e1c88971207b07f5944c6a06035fff72"><gtr:id>e1c88971207b07f5944c6a06035fff72</gtr:id><gtr:otherNames>Alton EWFW</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>2213-2600</gtr:issn><gtr:outcomeId>56cee59a360b00.41293314</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>0C770283-7E84-4462-9B66-431193C3E6E4</gtr:id><gtr:title>Current &amp;amp; Emerging Pharmaceutical Treatments for Cystic Fibrosis Lung Disease</gtr:title><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a4c54c9c32ea0c00850296e893333283"><gtr:id>a4c54c9c32ea0c00850296e893333283</gtr:id><gtr:otherNames>Alton E</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:outcomeId>56cde67e5ffb63.48503404</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>8F3B5420-7B91-4B3C-BB34-2A038CE6BB6F</gtr:id><gtr:title>Delivery of genes into the CF airway.</gtr:title><gtr:parentPublicationTitle>Thorax</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/4f76c57d4bc46e506eb309ab52020dbe"><gtr:id>4f76c57d4bc46e506eb309ab52020dbe</gtr:id><gtr:otherNames>Gill DR</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0040-6376</gtr:issn><gtr:outcomeId>546382af5adec6.92569935</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>1DBF6FB9-B327-4842-945D-AEE266C386D0</gtr:id><gtr:title>Moving forward: cystic fibrosis gene therapy.</gtr:title><gtr:parentPublicationTitle>Human molecular genetics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a009e137431ad6368363564a4ceb3ebc"><gtr:id>a009e137431ad6368363564a4ceb3ebc</gtr:id><gtr:otherNames>Griesenbach U</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0964-6906</gtr:issn><gtr:outcomeId>56cde4b079c663.89713165</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>B36E2F22-140B-4741-91E1-0589C0E9AF9E</gtr:id><gtr:title>Gene therapy in cystic fibrosis.</gtr:title><gtr:parentPublicationTitle>Archives of disease in childhood</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/3f4f77477ff061571cc14fdb80e92028"><gtr:id>3f4f77477ff061571cc14fdb80e92028</gtr:id><gtr:otherNames>Armstrong DK</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0003-9888</gtr:issn><gtr:outcomeId>pm_23607_27_24464978</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>E9F4141F-DAEB-4E13-8FD6-A89D664908FE</gtr:id><gtr:title>Expert opinion in biological therapy: update on developments in lung gene transfer.</gtr:title><gtr:parentPublicationTitle>Expert opinion on biological therapy</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a009e137431ad6368363564a4ceb3ebc"><gtr:id>a009e137431ad6368363564a4ceb3ebc</gtr:id><gtr:otherNames>Griesenbach U</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1471-2598</gtr:issn><gtr:outcomeId>546489e08b4bd5.96987130</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>1E96B5D8-3107-4AA1-96BD-483C06B76A96</gtr:id><gtr:title>A randomised, double-blind, placebo-controlled phase IIB clinical trial of repeated application of gene therapy in patients with cystic fibrosis.</gtr:title><gtr:parentPublicationTitle>Thorax</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/22f4b0c676241659342f5bf9f5c2ce79"><gtr:id>22f4b0c676241659342f5bf9f5c2ce79</gtr:id><gtr:otherNames>Alton EW</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0040-6376</gtr:issn><gtr:outcomeId>pm_23607_27_23525080</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>ED3B41E2-A999-4D58-B200-6A588D05BC4F</gtr:id><gtr:title>Self-reactive CFTR T cells in humans: implications for gene therapy.</gtr:title><gtr:parentPublicationTitle>Human gene therapy. Clinical development</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/ba83a03919e663abd4e3041dc76f8efc"><gtr:id>ba83a03919e663abd4e3041dc76f8efc</gtr:id><gtr:otherNames>Calcedo R</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>2324-8637</gtr:issn><gtr:outcomeId>pm_23607_27_23790242</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>1E855B64-A3A3-4E78-A513-9B4838444E02</gtr:id><gtr:title>A Randomised double-blind placebo controlled trial of repeated nebulisation of non-viral cystic fibrosis transmembrance conductance regulator gene therapy in patients with Cystic Fibrosis</gtr:title><gtr:parentPublicationTitle>A Randomised double-blind placebo controlled trial of repeated nebulisation of non-viral cystic fibrosis transmembrance conductance regulator gene therapy in patients with Cystic Fibrosis</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/22f4b0c676241659342f5bf9f5c2ce79"><gtr:id>22f4b0c676241659342f5bf9f5c2ce79</gtr:id><gtr:otherNames>Alton EW</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:outcomeId>58a2e6c51da6f5.32933507</gtr:outcomeId></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">MC_PC_12033</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>78FE8F42-8AFB-48F8-8662-37D541AD95BF</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>Congenital Disorders</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>DD81206B-5EB4-4BCC-AEF7-808A64606E0E</gtr:id><gtr:percentage>50</gtr:percentage><gtr:text>5.2  Cellular and gene therapies</gtr:text></gtr:researchActivity><gtr:researchActivity><gtr:id>0CDFB83C-594C-4860-B0BE-C82CA4D45B6B</gtr:id><gtr:percentage>50</gtr:percentage><gtr:text>6.2  Cellular and gene therapies</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>